

Table 2. Atezolizumab Efficacy by Cohort and Mutation Status									
PD-L1 Status, Mutation Status, and Cohort	No. of Patients	ORR per IRF, No. (%; 95% CI) ^a	Median DOR per IRF, months (95% CI) ^a	Median PFS per IRF, months (95% CI) ^a	Median OS, months (95% CI)				
All treated patients (TC2/3 or IC2/3)									
Cohort									
1	139	30 (22; 15 to 29)	9.8 (5.6 to NE)	5.4 (3.0 to 6.9)	20.1 (20.1 to NE)				
2	268	52 (19; 15 to 25)	NE (8.3 to NE)	2.8 (1.5 to 3.9)	15.5 (12.3 to NE)				
3	252	45 (18; 13 to 23)	11.8 (6.9 to NE)	2.8 (2.7 to 3.0)	13.2 (10.3 to 17.5)				
PD-L1 TC3 or IC3 subgroup									
Cohort									
1	65	20 (31; 20 to 43)	10.0 (6.9 to NE)	5.6 (2.7 to 8.3)	NE (12.0 to NE)				
2	122	32 (26; 19 to 35)	NE (8.3 to NE)	4.0 (1.5 to 5.5)	15.1 (12.0 to NE)				
3	115	31 (27; 15 to 36)	7.2 (5.6 to NE)	4.1 (2.8 to 5.6)	17.5 (11.1 to NE)				
EGFR mutation status ^b									
Cohort		Mutant	WT	Mutant	WT	Mutant	WT	Mutant	WT
1 ^c	117	3 (23; 5 to 54)	20 (19; 12 to 28)	NE (5.6 to NE)	8.5 (5.6 to 12.3)	5.5 (2.6 to 8.3)	5.5 (3.0 to 6.9)	20.1 (NE to NE)	NE (15.5 to NE)
2 ^d	219	0 (0; 0 to 19)	43 (21; 16 to 28)	NE (NE to NE)	NE (8.3 to NE)	1.3 (1.2 to 1.6)	2.8 (1.4 to 4.0)	9.8 (6.8 to NE)	16.3 (13.6 to NE)
3 ^e	207	1 (7; 0 to 34)	35 (18; 13 to 24)	NE (NE to NE)	16.4 (6.9 to NE)	1.4 (1.3 to 2.9)	2.8 (2.6 to 3.7)	7.4 (3.4 to 12.7)	14.1 (10.1 to NE)
KRAS mutation status									
Cohort									
1 ^f	100	9 (27; 13 to 46)	11 (16; 8 to 27)	10.0 (6.9 to NE)	7.1 (5.2 to 12.3)	8.3 (1.6 to 12.7)	4.8 (2.8 to 6.9)	NE (NE to NE)	NE (14.1 to 20.1)
2 ^g	290	16 (32; 20 to 47)	24 (16; 11 to 23)	11.9 (6.9 to NE)	NE (8.3 to NE)	4.1 (2.6 to 7.1)	1.4 (1.4 to 2.8)	17.7 (13.7 to NE)	15.1 (12.1 to NE)
3 ^h	188	10 (19; 9 to 31)	24 (18; 12 to 25)	NE (NE to NE)	16.4 (5.7 to NE)	2.6 (1.4 to 2.8)	2.8 (1.9 to 3.0)	12.1 (8.9 to NE)	13.8 (10.0 to NE)
Atezolizumab updated efficacy analysis ⁱ									
		ORR per INV, No. (%; 95% CI) ^j			Median OS (95% CI)	12-Month OS Rate (95% CI)			
All Treated Patients (TC2/3 or IC2/3)									
Cohort									
1	138 ^k	35 (25; 18 to 33)			23.5 (18.1 to NE)	66.4 (58.1 to 74.6)			
2	269 ^k	53 (20; 15 to 25)			15.5 (12.3 to 19.3)	58.1 (52.1 to 64.1)			
3	252	50 (20; 15 to 25)			13.2 (10.3 to 17.5)	52.3 (45.1 to 58.6)			
PD-L1 TC3 or IC3 Subgroup									
Cohort									
1	65	22 (34; 23 to 47)			26.9 (12.0 to NE)	61.5 (49.0 to 74.0)			
2	122	32 (26; 19 to 35)			16.6 (12.0 to NE)	58.7 (49.8 to 67.6)			
3	115	36 (31; 23 to 41)			17.5 (11.1 to 21.4)	57.5 (48.4 to 66.6)			

NOTE. On the basis of a data cutoff of December 1, 2015.
Abbreviations: DOR, duration of response; EGFR, epidermal growth factor receptor; INV, investigator; IRF, independent review facility; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; NE, not estimable; TC2/3 or IC2/3 = TC or IC ≥ 5% PD-L1-expressing cells, respectively; TC3 or IC3 = TC ≥ 50% or IC ≥ 10% PD-L1-expressing cells, respectively; WT, wild type.
^aAssessed by IRF per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
^bPatients were considered EGFR mutant for the analysis if their tumor tested positive for at least one of the following mutations: exon 19 deletions or insertions, L858R, exon 20 insertion, G719X, L861Q, or S768I. Three patients with a T790M mutation were not included in this analysis; two of these patients also had an exon 19 deletion.
^cNumber of patients tested: mutant (n = 13), WT (n = 104).
^dNumber of patients tested: mutant (n = 18), WT (n = 201).
^eNumber of patients tested: mutant (n = 14), WT (n = 193).
^fNumber of patients tested: mutant (n = 33), WT (n = 67).
^gNumber of patients tested: mutant (n = 50), WT (n = 150).
^hNumber of patients tested: mutant (n = 54), WT (n = 134).
ⁱOn the basis of an updated data cutoff of August 1, 2016; median duration of follow-up 22.5 months. Fewer than 50% of survival events had occurred at the time of data cutoff.
^jAssessed by INV per RECIST version 1.1.
^kOne patient was mistakenly assigned to cohort 2 at the time of the August 1, 2016, data cutoff.

Table 2. Atezolizumab Efficacy by Cohort and Mutation Status